B4GALT3

Across TCGA pan-cancer cohorts, B4GALT3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated B4GALT3 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher B4GALT3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated B4GALT3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, HNSC, and CCRCC are the cancer types where B4GALT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.534	0.836	<.001	25	view →
HNSC	DFS	Quartile	All	0.912	0.673	.007	17	view →
CCRCC	DFS	Median	All	1.000	0.839	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

B4GALT3–GBM (DFS)

Open the GBM breakdown →